12.02.2025 16:37:25
|
Alkermes Plc EPS Soars Past Forecasts
Alkermes (NASDAQ:ALKS), a biopharmaceutical company known for its innovative drugs targeting mental health and neurological disorders, announced its Q4 2024 earnings on Feb. 12. The company reported robust financial results, beating analyst estimates with a non-GAAP EPS of $1.04 against an expected $0.76. Revenue also exceeded projections, reaching $430 million compared to the $379 million forecast. Overall, the company delivered a strong quarter, driven by significant sales from its proprietary product portfolio, although challenges in manufacturing and royalties remain.Source: Alkermes. Analyst estimates for the quarter provided by FactSet.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Alkermes Inc.mehr Nachrichten
Keine Nachrichten verfügbar. |